Results 141 to 150 of about 26,228 (200)

Efficacy and safety of oral amantadine in Parkinson's disease with dyskinesia and motor fluctuations: a systematic review and meta-analysis of randomised controlled trials. [PDF]

BMJ Neurol Open
Rujirussawarawong S, Aungsumart S, Kasemsuk C, Limotai N.   +3 more
europepmc   +1 more source

Levodopa-induced dyskinesia in Parkinson's disease: an updated review of pharmacological treatments. [PDF]

Front Aging Neurosci
Chen F, Zhou C.
europepmc   +1 more source

Sydenham Chorea With Elevated Interleukin-12 Levels Responsive to Plasmapheresis and Immunotherapy. [PDF]

Cureus
Xu Z, Rosenberg J, Fekete R, Thomas AM.
europepmc   +1 more source

Amantadine as a therapeutic option for neuropathic pain in dogs with degenerative lumbosacral stenosis. [PDF]

BMC Vet Res
Caterino C, Della Valle G, Aragosa F, Cavalli S, Lamagna F, Fatone G.   +5 more
europepmc   +1 more source

Management of Parkinson's disease psychosis-a European perspective. [PDF]

Lancet Reg Health Eur
Pirker W, Ferreira JJ, Rascol O, Poewe W.   +3 more
europepmc   +1 more source

Comparing Parkinson's Disease Medications Categorised by Location in New South Wales, Australia: Linking the 45 and Up Study and the Pharmaceutical Benefits Scheme (PBS) Data. [PDF]

Aust J Rural Health
Logan PA, Micalos PS, Fealy S, Bramble M, Wong A.   +4 more
europepmc   +1 more source

Bat Influenza M2 Shows Functions Similar to Those of Classical Influenza A Viruses. [PDF]

Pathogens
Yang W, Wang L, Shi L, Zhang J, Liu H, Wang J, Ma W.   +6 more
europepmc   +1 more source

COVID-19 Pandemic Waves and 2024-2025 Winter Season in Relation to Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Blockers and Amantadine. [PDF]

Healthcare (Basel)
Puigdellívol-Sánchez A, Juanes-González M, Calderón-Valdiviezo AI, Losa-Puig H, González-Salvador M, León-Pérez M, Pueyo-Antón L, Franco-Romero M, Lozano-Paz C, Cortés-Borra A, Valls-Foix R.   +10 more
europepmc   +1 more source